GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Symbiotec Pharmalab Ltd

Symbiotec Pharmalab Reports Q2 FY27 Net Profit Rs. 52 Crs, Revenue Rs. 280 Crs

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 05 Nov 2026, 08:23 PM IST  ·  BSE ID: 87931bbd-a5bd-4a51-a6f3-2f0e62c777b4
View Original BSE Filing (PDF)
💡
In Simple Terms
Symbiotec Pharmalab's latest quarterly financial results show significant profit and revenue growth from its core business and new injectables.
🤖 AI Summary
  • Symbiotec Pharmalab reported Q2 FY27 consolidated Net Profit of Rs. 52 Crs, a 169% YoY increase.
  • Q2 FY27 consolidated Revenues reached Rs. 280 Crs, marking a 43% growth year-on-year.
  • API Business Operating Revenue for Q2 FY27 stood at Rs. 227 Crs, up 16% YoY.
  • H1 FY27 consolidated Net Profit was Rs. 66 Crs, increasing 34% YoY, with Revenues of Rs. 498 Crs.
  • Milestone-based revenue of Rs. 53 Crs from Complex Injectables was recognized in Q2 FY27.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Consol. PAT Q2 FY27
52 Rs. in Crs
169%
Consol. Revenues Q2 FY27
280 Rs. in Crs
43%
API Business Operating Revenue Q2 FY27
227 Rs. in Crs
16%
Consol. EBIDTA Q2 FY27
94 Rs. in Crs
88%
Consol. PAT H1 FY27
66 Rs. in Crs
34%
Consol. Revenues H1 FY27
498 Rs. in Crs
25%
Milestone based revenue from Complex Injectables Q2 FY27
53 Rs. in Crs
Net Debt as on 30th Sep 2026
314 Rs. in Crs
🏢 How This Affects the Company
📈
Business Impact
Consolidated revenues increased by 43% year-on-year in Q2 FY27, partly driven by Rs. 53 Crs from a licensing agreement for DCV products in the US. The API business continues to grow with 16% YoY operating revenue increase in Q2 FY27.
💰
Financial Impact
Consolidated Net Profit rose by 169% to Rs. 52 Crs in Q2 FY27. Consolidated EBIDTA for Q2 FY27 increased by 88% to Rs. 94 Crs.
⚙️
Operational Impact
The company successfully completed EUGMP and USFDA audits for its Rau and Pithampur plants, receiving approval certifications and EIRs. A first molecule ANDA for DCV was filed and accepted by USFDA.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this financial results update.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, which showed consolidated Net Profit of Rs. 52 Crs and Revenues of Rs. 280 Crs in Q2 FY27.
🔍
Management Signal
Management is signaling a focus on scaling emerging growth engines, including Complex Injectables and CDMO, alongside consistent API business performance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — monitor revenue contribution from new businesses.
Completion of 10-year take-or-pay agreement with Europe-based Alternate Protein player.
Commencement of commercial supplies for DCV products in the US market next year.
LOW RISK The filing reports strong financial performance and progress on new business initiatives.
💡 Investor Takeaway
Symbiotec Pharmalab reported Q2 FY27 consolidated Net Profit of Rs. 52 Crs, up 169% YoY, and consolidated Revenues of Rs. 280 Crs, up 43% YoY. The API business contributed Rs. 227 Crs to Q2 FY27 operating revenue. Rs. 53 Crs of milestone-based revenue from Complex Injectables was recognized.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 consolidated Net Profit grew 169% YoY to Rs. 52 Crs, demonstrating strong earnings acceleration.
  • Consolidated Revenues increased 43% YoY to Rs. 280 Crs in Q2 FY27, supported by new business segments.
📅 Company Track Record
Previous filing on 2026-11-05 also reported Symbiotec Pharmalab's Q2 FY27 Net Profit as Rs. 517.18 Million and revenue as Rs. 2,799.28 Million. This indicates consistency in reporting the Q2 FY27 financial figures.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Symbiotec Pharmalab's consolidated Net Profit in Q2 FY27?
Symbiotec Pharmalab's consolidated Net Profit in Q2 FY27 was Rs. 52 Crs, marking a 169% increase year-on-year.
What were Symbiotec Pharmalab's consolidated Revenues in Q2 FY27?
Symbiotec Pharmalab reported consolidated Revenues of Rs. 280 Crs in Q2 FY27, reflecting a 43% growth year-on-year.
How much revenue did Symbiotec Pharmalab recognize from Complex Injectables in Q2 FY27?
Symbiotec Pharmalab recognized milestone-based revenue of Rs. 53 Crs from Complex Injectables in Q2 FY27.
What was the API Business Operating Revenue for Symbiotec Pharmalab in Q2 FY27?
The API Business Operating Revenue for Symbiotec Pharmalab in Q2 FY27 was Rs. 227 Crs, showing a 16% year-on-year increase.
What is Symbiotec Pharmalab's Net Debt as of September 30, 2026?
Symbiotec Pharmalab's Net Debt as on September 30, 2026, stood at approximately Rs. 314 Crs.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.